About ReBEC
The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more
Everything you need to know about ReBEC
Click to access the hotsite
Click to download the PDF version
Existing fast tracks and support for other studies will not be interrupted. Priority assistance is granted to accelerate clinical research in epidemiological emergency situations and/or studies with potential to reduce socioeconomic inequalities, keeping a perspective aligned with the forefront of ethics and transparency, health diplomacy, scientific collaboration, and the diversity and specificities of recruitment and healthcare. Fast-Tracks in Operation>>
Instructions for the Registrant
We recommend reading the Registrant's Manual.
1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password.
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.
Clinical Research Volunteer
Would you like to become a volunteer in a clinical trial registered in ReBEC?
Access our FAQ to find out how.
Support channels:
* AI ReBEC@ (virtual assistant): automated support 24/7
* Humanized chat: Monday to Friday, from 8:00 AM to 12:00 PM (Brasília time), via this link
* Institutional WhatsApp / Dedicated Line: +55 21 97203-4750
Support from Monday to Friday, from 9:00 AM to 4:00 PM (Brasília time)
Priority and/or urgent administrative requests outside office hours may be sent to: plantao.rebec@gmail.com
We recommend including your username, associated email, or study registration number (RBR-xxxxxxx) with every request, when applicable, for faster assistance. Learn more
News
11/10/2026 | Joanne S. Eglovitch | RAPS
https://www.raps.org/resource/fda-commissioner-touts-strong-interest-in-early-stage-trial-pilot.html
Acting US Food and Drug Administration (FDA) Commissioner Kyle Diamantas said there is significant public interest in its recently announced Expedited Investigational New Drug (IND) pilot at the Friends of Cancer Research (FOCR) annual meeting on Tuesday.
Diamantas said the agency has received more than 100 applications and will select six to eight sponsors to participate in the pilot. The participants will be chosen next month, he said.
Both Diamantas and National Cancer Institute (NCI) Director Anthony Letai discussed some of the efforts being made to make early-stage US trials more competitive with countries such as China and Australia and said they are looking forward to working together as partners in Operation TrialBlazer.
The expedited IND pilot is part of Operation TrialBlazer, which was launched in mid-June and features a series of measures designed to speed up drug development from the IND stage to late-stage clinical trials. In the Expedited IND pilot, qualified external institutions will collaborate with sponsors to develop and review protocols for first-in-human (FIH) clinical trials intended for IND submissions to the FDA. (RELATED: HHS and FDA propose clinical trial reforms to expedite drug development, Regulatory Focus 23 June 2026)
Through these programs, FDA and NCI will be working together to streamline clinical research. FDA’s part in the effort is to accelerate early-stage, first-in-human clinical trials and to streamline IND applications while NCI’s role is to collaborate with cancer centers and researchers to streamline clinical trial activation timelines and improve patient enrollment in cancer studies.
…11/11/2026 | Doherty Institute
How a promising antibody discovered in a person who recovered from COVID-19 progressed from the laboratory to a first-in-human clinical trial.
The COVID-19 pandemic highlighted the need for treatments that can be rapidly developed against emerging infectious diseases. One promising approach is the use of monoclonal antibodies, laboratory-made versions of the body’s natural immune defences that can help prevent or treat viral infections. Researchers from the University of Melbourne, WEHI and collaborating institutions spent five years developing one such antibody, PDI204, taking it from discovery in a person who recovered from COVID-19 through to a Phase I clinical trial in healthy volunteers. While the virus continued to evolve, the project provides valuable lessons for developing antibody therapies against future pandemic threats.
Finding the right antibody: learning from natural immunity
The journey began at the start of the pandemic, when a team of researchers at the University of Melbourne – including Professor Stephen Kent, Associate Professor Adam Wheatley, Associate Professor Jennifer Juno, and Dr Wen Shi Lee – studied a cohort of people who had recovered from COVID-19. After infection with SARS-CoV-2, the virus that causes COVID-19, a person’s B cells keep memory of the virus and can make antibodies against it. The team isolated these memory B cells from people who had recovered from COVID-19 and created a library of antibodies that could be used as potential treatments for SARS-CoV-2.
From a promising candidate to an antiviral treatment
Finding an antibody…
Username/Password
Public trial
Effect and safety of OnabotulinumtoxinA injection into the penis compared with placebo for the treatment of erectile dysfunction
Date of registration: 11/16/2026 (mm/dd/yyyy)Last approval date : 11/16/2026 (mm/dd/yyyy)
Last revision: 1
Study type: Interventional
Comparison between online training and an artificial intelligence tool in pain education: a randomized clinical trial
Date of registration: 11/16/2026 (mm/dd/yyyy)Last approval date : 11/16/2026 (mm/dd/yyyy)
Last revision: 1
Study type: Interventional
Physical activity level and clinical, functional, and survival outcomes in patients with lung and/or head and neck Cancer during standard oncological treatment
Date of registration: 11/16/2026 (mm/dd/yyyy)Last approval date : 11/16/2026 (mm/dd/yyyy)
Last revision: 1
Study type: Observational
Analysis of the Efficacy of Two Laser Therapy Protocols in the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
Date of registration: 11/16/2026 (mm/dd/yyyy)Last approval date : 11/16/2026 (mm/dd/yyyy)
Last revision: 1
Study type: Interventional
Use of a mobile device to monitor the baby's well-being during pregnancy in the brazilian public health system
Date of registration: 11/16/2026 (mm/dd/yyyy)Last approval date : 11/16/2026 (mm/dd/yyyy)
Last revision: 1
Study type: Observational
Influence of melatonin on physiological responses and physical performance during and after running
Date of registration: 05/26/2025 (mm/dd/yyyy)Last approval date : 11/14/2026 (mm/dd/yyyy)
Last revision: 2
Study type: Interventional
Training with recall techniques improves the identification and correction of problems between the patient and the mechanical ventilator.
Date of registration: 06/10/2026 (mm/dd/yyyy)Last approval date : 11/13/2026 (mm/dd/yyyy)
Last revision: 4
Study type: Interventional
Total de Ensaios Clínicos 19315.
Existem 9866 ensaios clínicos registrados.
Existem 5306 ensaios clínicos recrutando.
Existem 144 ensaios clínicos em análise.
Existem 6379 ensaios clínicos em rascunho.